Tags

Type your tag names separated by a space and hit enter

Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
J Alzheimers Dis. 2016; 50(3):765-78.JA

Abstract

Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating mild cognitive impairment (MCI) patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t-tau, Aβ1-42, p-tau181, p-tau199, and p-tau231). VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau. VILIP-1/Aβ(1-42) and VILIP-1/p-tau181 ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ(1-42) and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/p-tau181, and VILIP-1/p-tau231 ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Babić Leko M
Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia.
Borovečki F
Department for Functional Genomics, Center for Translational and Clinical Research, University of Zagreb Medical School, University Hospital Center Zagreb, Zagreb, Croatia.
Dejanović N
General Hospital Vinkovci, Vinkovci, Croatia.
Hof PR
Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Šimić G
Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia.

MeSH

AdultAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesCognitive DysfunctionDiagnosis, DifferentialDisease ProgressionFemaleHumansMaleMental Status ScheduleMiddle AgedNeurocalcinPeptide FragmentsPredictive Value of TestsROC CurveStatistics as Topictau Proteins

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26836160

Citation

Babić Leko, Mirjana, et al. "Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients With Mild Cognitive Impairment." Journal of Alzheimer's Disease : JAD, vol. 50, no. 3, 2016, pp. 765-78.
Babić Leko M, Borovečki F, Dejanović N, et al. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment. J Alzheimers Dis. 2016;50(3):765-78.
Babić Leko, M., Borovečki, F., Dejanović, N., Hof, P. R., & Šimić, G. (2016). Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease : JAD, 50(3), 765-78. https://doi.org/10.3233/JAD-150705
Babić Leko M, et al. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients With Mild Cognitive Impairment. J Alzheimers Dis. 2016;50(3):765-78. PubMed PMID: 26836160.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment. AU - Babić Leko,Mirjana, AU - Borovečki,Fran, AU - Dejanović,Nenad, AU - Hof,Patrick R, AU - Šimić,Goran, PY - 2016/2/3/entrez PY - 2016/2/3/pubmed PY - 2016/11/1/medline KW - Alzheimer’s disease KW - biomarker KW - cerebrospinal fluid KW - dementia KW - early diagnosis KW - mild cognitive impairment KW - visinin-like protein 1 (VILIP-1) SP - 765 EP - 78 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 50 IS - 3 N2 - Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer's disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating mild cognitive impairment (MCI) patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t-tau, Aβ1-42, p-tau181, p-tau199, and p-tau231). VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau. VILIP-1/Aβ(1-42) and VILIP-1/p-tau181 ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ(1-42) and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/p-tau181, and VILIP-1/p-tau231 ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/26836160/Predictive_Value_of_Cerebrospinal_Fluid_Visinin_Like_Protein_1_Levels_for_Alzheimer's_Disease_Early_Detection_and_Differential_Diagnosis_in_Patients_with_Mild_Cognitive_Impairment_ DB - PRIME DP - Unbound Medicine ER -